Clasp Therapeutics Doses First Patient in Phase 1 Clinical Trial with a First-in-Class T-Cell Engager Designed to Target Cancer Cells with Absolute Specificity

GO BACK TO PRESS RELEASES & MEDIA Press Release April 28, 2025 Clasp Therapeutics Doses First Patient in Phase 1 Clinical Trial with a First-in-Class T-Cell Engager Designed to Target Cancer Cells with Absolute Specificity CLSP-1025 targets the most common p53 mutation, a key oncogenic driver associated with multiple types of solid tumors, including gastrointestinal, lung, and gynecological cancers Clasp’s pHLAre™ platform is optimized for tumor-specific antigens, with the potential to yield safer and more effective precision immunotherapies Preclinical data presented at the 2025 American Asso